US-based women’s healthcare firm Gynesonics has secured CE Mark approval for its next-generation VizAblate System designed for treatment of symptomatic uterine fibroids.

The CE Mark allows the company to market its proprietary VizAblate System across the European Union (EU).

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Gynesonics president and CEO Christopher Owens said: "This regulatory clearance is an important milestone for the organisation.

"We look forward to sharing additional clinical data while moving forward with our commercialisation strategy to provide millions of women with a novel and less-invasive solution to treat their symptomatic uterine fibroids."

"We look forward to sharing additional clinical data while moving forward with our commercialisation strategy to provide millions of women with a novel and less-invasive solution to treat their symptomatic uterine fibroids."

VizAblate integrates ultrasound image guidance and radiofrequency ablation into a single handheld device.

The device uses radiofrequency energy to ablate fibroids under intrauterine sonography guidance.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The company said that users can visually target specific fibroids and optimise ablations within them with the new VizAblate device and software.

VizAblate’s transcervical access is simple, is associated with short procedure times, requires minimal in-procedure assistance, and is incision-free.

The VizAblate system features proprietary intrauterine ultrasound probe that provides high-resolution, clear image and it does not violate the uterine serosa or peritoneal cavity and is a distinct alternative to power morcellation procedures.

According to the company, physicians familiar with the previous VizAblate device are also looking forward to the deployment of the next-generation design.

Vrije Universiteit Medisch Centrum gynecologist Hans Brölmann said: "The imaging is clear and the ease of use will provide gynecologists with an exciting new fibroid treatment that delivers short procedure times."